The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
Abstract
CONTEXT: Pramipexole and levodopa are effective medications to treat motor symptoms of early Parkinson disease (PD). In vitro and animal studies suggest that pramipexole may protect and that levodopa may either protect or damage dopamine neurons. Neuroimaging offers the potential of an objective biomarker of dopamine neuron degeneration in PD patients. OBJECTIVE: To compare rates of dopamine neuron degeneration after initial treatment with pramipexole or levodopa in early PD by means of dopamine transporter imaging using single-photon emission computed tomography (SPECT) with 2beta-carboxymethoxy-3beta(4-iodophenyl)tropane (beta-CIT) labeled with iodine 123. DESIGN: Substudy of a parallel-group, double-blind randomized clinical trial. SETTING AND PATIENTS: Eighty-two patients with early PD who were recruited at 17 clinical sites in the United States and Canada and required dopaminergic therapy to treat emerging disability, enrolled between November 1996 and August 1997. INTERVENTIONS: Patients were randomly assigned to receive pramipexole, 0.5 mg 3 times per day with levodopa placebo (n = 42), or carbidopa/levodopa, 25/100 mg 3 times per day with pramipexole placebo (n = 40). For patients with residual disability, the dosage was escalated during the first 10 weeks, and subsequently, open-label levodopa could be added. After 24 months of follow-up, the dosage of study drug could be further modified. MAIN OUTCOME MEASURES: The primary outcome variable was the percentage change from baseline in striatal [(123)I]beta-CIT uptake after 46 months. The percentage changes and absolute changes in striatal, putamen, and caudate [(123)I]beta-CIT uptake after 22 and 34 months were also assessed. Clinical severity of PD was assessed using the Unified Parkinson Disease Rating Scale (UPDRS) 12 hours off anti-PD medications. RESULTS: Sequential SPECT imaging showed a decline in mean (SD) [(123)I]beta-CIT striatal uptake from baseline of 10.3% (9.8%) at 22 months, 15.3% (12.8%) at 34 months, and 20.7% (14.4%) at 46 months-approximately 5.2% per year. The mean (SD) percentage loss in striatal [(123)I]beta-CIT uptake from baseline was significantly reduced in the pramipexole group compared with the levodopa group: 7.1% (9.0%) vs 13.5% (9.6%) at 22 months (P =.004); 10.9% (11.8%) vs 19.6% (12.4%) at 34 months (P =.009); and 16.0% (13.3%) vs 25.5% (14.1%) at 46 months (P =.01). The percentage loss from baseline in striatal [(123)I]beta-CIT uptake was correlated with the change from baseline in UPDRS at the 46-month evaluation (r = - 0.40; P =.001). CONCLUSIONS: Patients initially treated with pramipexole demonstrated a reduction in loss of striatal [(123)I]beta-CIT uptake, a marker of dopamine neuron degeneration, compared with those initially treated with levodopa, during a 46-month period. These imaging data highlight the need to further compare imaging and clinical end points of PD progression in long-term studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Parkinsonism: Onset, progression, and mortality
Hoehn, M., & Yahr, M. (2011) · Neurology · doi:10.1212/01.wnl.0000405146.06300.91 · Cited by 1,061
Core assessment program for intracerebral transplantations (CAPIT)
Langston, J. W., Widner, H., Goetz, C. G., Brooks, D., Fahn, S., Freeman, T., & Watts, R. (1992) · Movement Disorders · doi:10.1002/mds.870070103 · Cited by 1,008
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
Rate of cell death in parkinsonism indicates active neuropathological process
McGeer, P. L., Itagaki, S., Akiyama, H., & McGeer, E. G. (1988) · Annals of Neurology · doi:10.1002/ana.410240415 · Cited by 556
Intent-to-Treat Analysis for Longitudinal Studies with Drop-Outs
Little, R., & Yau, L. (1996) · Biometrics · doi:10.2307/2532847 · Cited by 380
Innis, R. B., Seibyl, J. P., Scanley, B. E., Laruelle, M., Abi-Dargham, A., Wallace, E., Baldwin, R. M., Zea-Ponce, Y., Zoghbi, S., & Wang, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11965 · Cited by 359
The response to levodopa in parkinson's disease: Imposing pharmacological law and order
Nutt, J. G., & Holford, N. H. G. (1996) · Annals of Neurology · doi:10.1002/ana.410390504 · Cited by 299
van Dyck, C. H., Seibyl, J. P., Malison, R. T., Laruelle, M., Zoghbi, S. S., Baldwin, R. M., & Innis, R. B. (2002) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200201000-00005 · Cited by 251
Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
Fahn, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.529 · Cited by 245
Murer, M. G., Dziewczapolski, G., Menalled, L. B., García, M. C., Agid, Y., Gershanik, O., & Raisman‐Vozari, R. (1998) · Annals of Neurology · doi:10.1002/ana.410430504 · Cited by 232
Iida, M., Miyazaki, I., Tanaka, K.-I., Kabuto, H., Iwata-Ichikawa, E., & Ogawa, N. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01688-1 · Cited by 211
Dopamine agonists and neuroprotection in parkinson's disease
Olanow, C. W., Jenner, P. G., & Brooks, D. J. (1998) · Annals of Neurology · doi:10.1002/ana.410440725 · Cited by 131
The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease
Ahlskog, J. E., Uitti, R. J., O’Connor, M. K., Maraganore, D. M., Matsumoto, J. Y., Stark, K. F., Turk, M. F., & Burnett, O. L. (1999) · Movement Disorders · doi:10.1002/1531-8257(199911)14:6<940::aid-mds1005>3.0.co;2-y · Cited by 105
Are Dopamine Receptor Agonists Neuroprotective in Parkinson??s Disease?
Le, W., & Jankovic, J. J. (2001) · Drugs & Aging · doi:10.2165/00002512-200118060-00001 · Cited by 100
Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole
Carvey, P. M., Pieri, S., & Ling, Z. D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01273182 · Cited by 97
Hardie, R. J., & Morrish, P. (1999) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.256 · Cited by 28
Cited by
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Levodopa and the Progression of Parkinson's Disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa033447 · Cited by 1,821
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
The diagnosis of Parkinson’s disease
Tolosa, E., Wenning, G., & Poewe, W. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70285-4 · Cited by 902
Metadata
- Authors
- Parkinson Study Group
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-04-03
- Volume
- 287
- Issue
- 13
- Pages
- 1653
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4250151684
- Cited by
- 711
- References
- 20
- FWCI
- 38.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.